



Constrained peptides Unconstrained thinking

bicycle therapeutics

NASDAQ: BCYC May 2022

Forward-looking statements

This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts", "goal," "intends," "may" "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements, including statements regarding: our future financial or business performance, conditions, plans, prospects, or strategies and other financial and business matters; and our current and prospective product candidates, ongoing and planned clinical trials and preclinical activities, current and prospective collaborations and the timing and success of our development of our anticipated product candidates.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results, our plans to initiate clinical trials and the designs of the planned trials and other future conditions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forwardlooking statements. These risks and uncertainties include, but are not limited to, risks related to the ongoing COVID-19 pandemic, the risk that any one or more of our product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials, the risk that we may not realize the intended benefits of our technology, including that we may not identify and develop additional product candidates for our pipeline, the risk that we may not maintain our current collaborations or enter into new collaborations in the future, or that we may not realize the intended benefits of these collaborations, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results will not be replicated or will not continue in ongoing or future studies or trials, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that the size and potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-parties, risks regarding the accuracy of our estimates of expenses, risks relating to our capital requirements and needs for additional financing, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 1, 2022, as well as in other filings we may make with the SEC in the future, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.




Clinical stage biopharma company pioneering Bicycles – a new differentiated class of innovative medicines

Unique	Internal	Validating	Ambitious
Platform	Programs	Partnerships	Company
Generating Bicycles – a novel synthetic peptide modality that enables complex previously undruggable targets to be drugged. Bicycle [®] modular format platform based on Nobel Prize science. Strong intellectual property portfolio.	Focused on oncology and immuno-oncology with multiple Phase I/II clinical assets (BT5528, BT8009 and BT7480). BT5528 and BT8009 have shown preliminary signs of anti-tumor activity. Trial updates for BT5528 and BT8009 in 2022.	<text><image/><image/><image/><image/><image/><image/><image/><image/></text>	Deeply experienced team Located in Cambridge UK and Lexington, MA ~149 Employees* NASDAQ: BCYC Cash balance \$407.4M* (expected cash runway through 2024)



Bicycles are a new therapeutic modality – bicyclic peptides



DIC

therapeutics




Bicycles are designed to combine the advantages of both small molecules and antibodies

	\mathbf{Q}	×	
	Bicycle®	Small molecule	Antibody
Small size	Yes 1.5-2kDa	Yes <0.8kDa	No >150kDA
Specificity	High	Low	Multiple
Chemical synthesis (NCEs)	Yes	Yes	No
Rapid tissue penetration	Yes	Yes	No
Complex protein targets druggable	Yes	Limited	Yes
Route of elimination	Renal	Liver	Liver

bicycle therapeutics


May 2022

Bicycle® platform delivers a toolkit of building blocks to create novel medicines



therapeutics

BTCs – preclinical data indicates higher potency and specificity with fewer side effects than ADCs



therapeutics


Pipeline



Business strategy designed to explore full potential of *Bicycle*[®] technology

Oncology

Bicycles are well suited for solid tumors, which are the majority of all cancers. Limited established treatments and high-medical need.



Binders e.g., Tumor Antigens, T-Cell Receptors, NK Cell Receptors, Transporters



Other serious diseases

Exploring broad application of *Bicycles* beyond oncology through partnerships with leading therapeutic experts





Robust proprietary and partnered pipeline

Target / Product	Partner / Sponsor	Indication	Modality	Pre- clinical	IND- enabling	Phase I	Phase II
Internal programs							
BT5528 (EphA2)		Oncology	Bicycle [®] Toxin Conjugate				
BT8009 (Nectin-4)		Oncology	Bicycle [®] Toxin Conjugate				
BT7480 (Nectin-4/CD137)		Immuno-oncology	Bicycle TICA™				
BT7455 (EphA2/CD137)		Immuno-oncology	Bicycle TICA™				
Partnered programs							
THR-149 (Kallikrein inhibitor Bicycle)	OXURION°	Ophthalmology					
BT1718 (MT1-MMP)	CANCER RESEARCH UK	Oncology	Bicycle [®] Toxin Conjugate				
BT7401 (multivalent CD137 systemic agonist)	CANCER RESEARCH UK	Immuno-oncology					
Undisclosed	Genentech A Member of the Roche Group	Immuno-oncology					
Inhaled Bicycles	AstraZeneca	Respiratory					
Novel anti-infectives	Innovate UK	Anti-infectives					
Novel CNS targets	Dementia Discovery Fund	CNS					
Novel neuromuscular targets	IONIS	Neuromuscular					



BT8009 Monotherapy Nectin-4



BT8009: Status of Phase I dose escalation*

Promising clinical activity seen at 5mg/m² QW in urothelial carcinoma (UC); dose well tolerated, with signs of differentiation compared to antibodies and potential for industry-leading product profile

- 50% ORR and 75% disease control, including 1 (13%) complete response
- Durable responses, with tumor reductions maintained over time

Expect to declare 5mg/m² QW recommended Phase II dose (RP2D)

Also exploring additional, less frequent doses and one additional dose could be selected for Phase II


Expect to provide further updates on clinical progress later in 2022

* All BT8009 data as of 7Mar22



BT8009: Dose escalation progress and strategy

3+3 escalation design: MTD reached for weekly schedule and one go-forward dose identified. Currently investigating alternative dosage regimens as per FDA's Project Optimus guidelines



BT8009: Overview of key demographics for all patients enrolled in Phase I dose escalation trial

Demographics	
Total	N=37
Age, years, median (range)	66 (44-83)
Sex, n (%)	
Male	22 (59%)
Female	15 (41%)
ECOG, n (%)	
0 (Good performance status)	15 (41%)
1	22 (59%)
Prior therapies, median	3
Screened for Nectin-4, n (%)	0



BT8009: Overview of disease history for all patients enrolled in Phase I dose escalation trial

Demographics	
Total	N=37
Tumor type	
Breast	4 (11%)
Esophageal	1 (3%)
Head/Neck	2 (5%)
Lung	5 (14%)
Ovarian	1 (3%)
Pancreatic	6 (16%)
Urothelial	18 (49%)



BT8009: Response-evaluable response¹ rates in urothelial cancer

Best overall response, N (%)	2.5mg/m² QW (N=4)	5mg/m² QW (N=8)	7.5mg/m² Q2W (N=2)	7.5mg/m² QW (N=2)²	Total (N=16)
Complete Response	0	1 (13)	0	0	1 (6)
Partial Response	1 (25)	3 (38)	0	1 (50)	5 (31)
Stable Disease	2 (50)	2 (25)	0	1 (50)	5 (31)
Progressive Disease	1 (25)	2 (25)	2 (100)	0	5 (31)
ORR (CR+PR)	1 (25)	4 (50)	0	1 (50)	6 (38)
DCR ³ (CR+PR+SD)	3 (75)	6 (75)	0	2 (100)	11 (69)

1. Responses under response evaluation criteria in solid tumors (RECIST) version 1.1

2. Excludes two non-evaluable patients who came off trial before their first scans

3. Disease control rate




BT8009: Responses^{*} observed in 5mg/m² QW cohort Phase I dose escalation in response-evaluable urothelial patients

Urothelial responses:

- 4 responses in 8 patients
 - 1 Complete response
 - 3 Partial responses
 - 71% tumor reduction

(100% reduction in target lesion)

- 65% tumor reduction
- 54% tumor reduction
- Median DoR not reached
 - 3 responses ongoing
 - 1 progression at ~3 months




One subject who had clinical progression did not have post-baseline RECIST assessment data and is thereby omitted from this figure. **In Sept 2021, site entered patient as progressive disease (PD) in target lesion. Subsequent to the Oct 2021 BT8009 update, the site updated patient as stable disease (SD) in target lesion but PD in non-target lesion.

* Responses under response evaluation criteria in solid tumors (RECIST) version 1.1



BT8009: Comparison of complete responder^{*} pre-dose tumor images with tumor images after six months treatment (5mg/m² QW)



* Response under response evaluation criteria in solid tumors (RECIST) version 1.1

May 2022

therapeutics

BT8009: Overview of adverse events across all cohorts. Well tolerated below 7.5mg/m² QW

	Treatment Emergent Adverse Events and Treatment Related Adverse Events													
Dose Cohort	All C	ohorts	2.5m	g/m² QW	5mg/r	m ² QW UC	5mg/m ² (QW non-UC	5mg/	/m ² QW	7.5mg/	/m ² Q2W	7.5m	g/m ² QW
N	:	37		7		8		12		20		5		5
	Total	Treatmt Rel	Total	Treatmt Rel	Total	Treatmt Rel	Total	Treatmt Rel	Total	Treatmt Rel	Total	Treatmt Rel	Total	Treatmt Rel
TEAE ≥15%	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Fatigue	15 (41)	12 (32)	4 (57)	4 (57)	1 (13)	0	7 (58)	5 (42)	8 (40)	5 (25)	2 (40)	2 (40)	1 (20)	1 (20)
Nausea	14 (38)	13 (35)	5 (71)	4 (57)	3 (38)	3 (38)	4 (33)	4 (33)	7 (35)	7 (35)	1 (20)	1 (20)	1 (20)	1 (20)
Diarrhea	12 (32)	9 (24)	4 (57)	3 (43)	3 (38)	2 (25)	2 (17)	1 (8)	5 (25)	3 (15)	0	0	3 (60)	3 (60)
Pyrexia	12 (32)	8 (22)	2 (29)	1 (14)	4 (50)	2 (25)	1 (8)	2 (25)	5 (25)	4 (20)	2 (40)	1 (20)	3 (60)	2 (40)
Anemia	12 (32)	6 (16)	2 (29)	1 (14)	2 (25)	0	6 (50)	4 (33)	8 (40)	4 (20)	0	0	2 (40)	1 (20)
Decreased appetite	12 (32)	8 (22)	3 (43)	3 (43)	1 (13)	1 (13)	8 (67)	4 (33)	9 (45)	5 (25)	0	0	0	0
Constipation	11 (30)	2 (5)	2 (29)	1 (14)	2 (25)	0	3 (25)	0	5 (25)	0	1 (20)	0	3 (60)	1 (20)
Urinary tract infection	10 (27)	0	2 (29)	0	5 (63)	0	1 (8)	0	6 (30)	0	1 (20)	0	1 (20)	0
Neutrophil count decrease ¹	8 (22)	8 (22)	0	0	0	0	4 (33)	4 (33)	4 (20)	4 (20)	1 (20)	1 (20)	3 (60)	3 (60)
Asthenia	9 (24)	9 (24)	1 (14)	1 (14)	2 (25)	2 (25)	1 (8)	1 (8)	3 (15)	3 (15)	2 (40)	2 (40)	3 (60)	3 (60)
Peripheral neuropathy ^{2,3}	9 (24)	7 (19)	2 (29)	2 (29)	4 (50)	4 (50)	1 (8)	1 (8)	5 (25)	5 (25)	1 (20)	0	1 (20)	0
Peripheral sensory neuropathy	4 (11)	3 (8)	0	0	2 (25)	2 (25)	1 (8)	1 (8)	3 (15)	3 (15)	0	0	1 (20)	0
Other peripheral neuropathy	5 (14)	4 (11)	2 (29)	2 (29)	2 (25)	2 (25)	0	0	2 (10)	2 (10)	1 (20)	0	0	0
Abdominal pain	8 (22)	1 (3)	2 (29)	1 (14)	1 (13)	0	3 (25)	0	4 (20)	0	0	0	2 (40)	0
Pruritus	7 (19)	5 (14)	3 (43)	3 (43)	0	0	1 (8)	0	1 (5)	0	2 (40)	1 (20)	1 (20)	1 (20)
Alopecia	7 (19)	7 (19)	0	0	3 (38)	3 (38)	1 (8)	1 (8)	4 (20)	4 (20)	1 (20)	1 (20)	2 (40)	2 (40)
Rash	7 (19)	5 (14)	2 (29)	2 (29)	2 (25)	2 (25)	2 (17)	0	4 (20)	2 (10)	1 (20)	1 (20)	0	0
Back pain	6 (16)	0	1 (14)	0	2 (25)	0	2 (17)	0	4 (20)	0	0	0	1 (20)	0
Hypokalemia	6 (16)	2 (5)	1 (14)	0	0	0	4 (33)	1 (8)	4 (20)	1 (5)	0	0	1 (20)	1 (20)
Hypomagnesia	6 (16)	2 (5)	1 (14)	1 (14)	1 (13)	0	3 (25)	0	4 (20)	0	0	0	1 (20)	1 (20)

1. Previous neutrophil count decrease total included neutrophilia leukocytosis (neutrophil count increase). This event has been removed from current total.

2. Peripheral neuropathy includes peripheral sensory neuropathy (4 total, 3 related), paresthesia (1,1), hypoesthesia (1,1), neuropathy peripheral (1,1), neurotoxicity (1,1), and hemiparesis (1,0)

Due to rounding, the sum of the percentages of peripheral sensory neuropathy and other sensory neuropathy do not equal peripheral neuropathy for all cohorts TEAE



19

In enfortumab vedotin Phase I trial: "Peripheral neuropathy (of any form)...occurred in 76 patients (49%)"¹

"Peripheral sensory neuropathy was the most common reason for discontinuation as a result of an AE (5 of 16 patients)"¹

	EV 0.50 mg/kg (n = 2)		EV 0.75 (n =		EV 1.0 mg/kg (n = 27)		EV 1.25 mg/kg (n = 112)	
TRAE	AII	≥ 3	All	≥ 3	AII	≥ 3	All	≥ 3
Fatigue	0	0	3 (21)	0	9 (33)	1 (4)	59 (53)	2 (2)
Alopecia	0	0	2 (14)	0	7 (26)	0	52 (46)	0
Decreased appetite	0	0	1 (7)	0	8 (30)	0	47 (42)	1 (1)
Dysgeusia	0	0	2 (14)	0	7 (26)	0	43 (38)	0
Nausea	0	0	4 (29)	0	12 (44)	0	42 (38)	1 (1)
Peripheral sensory neuropathy ²	0	0	2 (14)	0	5 (19)	0	42 (38)	1(1)
Pruritus	0	0	1 (7)	0	11 (41)	0	39 (35)	1 (1)
Diarrhea	1 (50)	0	3 (21)	0	7 (26)	0	37 (33)	1 (1)
Maculopapular rash	0	0	0	0	3 (11)	2 (7)	30 (27)	3 (3)
AST increased	0	0	0	0	5 (19)	0	25 (22)	1 (1)
Dry skin	0	0	1 (7)	0	1 (4)	0	24 (21)	0

49% incidence of Any Peripheral Neuropathy, across all cohorts. Supplemental Appendix, Table S2¹

1. Rosenberg, et al., "EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma" Journal of Clinical Oncology, 2020 Apr 1; 38(10): 1041–1049

2. This definition excludes other forms of peripheral neuropathy (PN) that are included in BT8009's definition of PN: paresthesia, hypoesthesia, neuropathy peripheral, neurotoxicity, and hemiparesis



BT8009 patients on trial experienced limited dose modifications below 7.5mg/m² QW

N (%)	2.5mg/m ² QW (N=7)	5mg/m² QW (N=20)	7.5mg/m² Q2W (N=5)	7.5mg/m² QW (N=5)	All Cohorts (N=37)
Discontinuations ¹	1 (14)	1 (5)	0	0	2 (5)
Interruptions ²	2 (29)	6 (30)	0	3 (60)	11 (30)
Reductions ³	0	4 (20)	0	2 (40)	6 (16)

1. Neither incident was treatment-related

2. 19 of 28 incidents were treatment related: fatigue (4), asthenia (3), anemia (3), paresthesia, neurotoxicity-hands, transaminitis, creatinine increase, fever, neutropenia, neutrophil count decrease, neutrophilia leukocytosis, myalgia

3. All incidents were treatment related: neutropenia (2), asthenia (2) neutrophil count decrease, hypokalemia, neurotoxicity



BT8009: Summary of treatment-related and serious adverse events

# of patients with at least one:	2.5mg/m² QW (N=7)	5mg/m² QW (N=20)	7.5mg/m² Q2W (N=5)	7.5mg/m² QW (N=5)	Total (N=37)
Related TEAE	7 (100)	17 (85)	5 (100)	5 (100)	34 (92)
Related TEAE, \geq Gr3	1 (14)	3 (15)	1 (20)	4 (80)	9 (24)
Related TEAE, Gr3 ¹	1 (14)	2 (10)	1 (20)	4 (80)	8 (22)
Related TEAE, Gr4 ²	0	2 (10)	0	3 (60)	5 (14)
Related TEAE, Gr5	0	0	0	0	0
TESAE	2 (29)	4 (20)	1 (20)	0	7 (19)
TESAE, ≥Gr3	1 (14)	3 (15)	1 (20)	0	5 (14)
Related TESAE ³	0	1 (5)	0	0	1 (3)
Related TESAE, \geq Gr3	0	0	0	0	0
Dose Limiting Toxicity ⁴	0	0	0	2 (40)	2 (5)

1. 2.5mg/m² QW: fatigue. 5mg/m² QW: fatigue, asthenia. 7.5mg/m² Q2W: hypertension. 7.5mg/m² QW: asthenia, diarrhea, neutrophil count decrease, neutropenia.

2. 5mg/m² QW: neutrophil count decrease, hypokalemia. 7.5mg/m² QW: neutrophil count decrease, hypokalemia, neutrophia.

3. Vomiting

4. DLTs: asthenia and neutrophil count decrease



BT8009: The incidence of neutropenia^{*} was dose dependent and low below 7.5mg/m² QW

- Neutrophil decrease findings were transient in nature and monitorable, measurable and treatable; prophylactic G-CSF was not utilized in the Phase I but will be in Phase II
- Incidence of lab recorded neutropenia was 2 of 37 or 5%, with 0% incidence of febrile neutropenia

Cohort-by-cohort description of neutropenia* incidence						
Dose (mg/m ²)	Grade 2-4	Grade 3-4				
2.5 QW	0/7 (0%)	0/7 (0%)				
5 QW	4/20 (20%)	2/20 (10%)				
7.5 Q2W	0/5 (0%)	0/5 (0%)				
7.5 QW	3/5 (60%)	3/5 (60%)				
All doses	7/37 (19%)	5/37 (14%)				
Below 7.5 QW	4/32 (13%)	2/32 (6%)				

* Neutropenia includes 8 cases of neutrophil count decreases and 2 cases recorded as neutropenia



Enfortumab vedotin: Neutropenia incidence and severity from label*

Neutrophil count decrease at 1.25mg/kg							
Study (N)	Grade 2-4	Grade 3-4					
EV-201 C1 (125)	14%	5%					
EV-201 C2 (89)	34%	5%					
EV-301 (296)	27%	12%					



24



BT8009: Low incidence and severity of rash

Treatment Emergent Adverse Events and Treatment Related Adverse Events														
Dose Cohort	All C	ohorts	2.5m	g/m² QW	5mg/n	n ² QW UC	5mg/m ² C	QW non-UC	5mg/	′m² QW	7.5mg/	/m ² Q2W	7.5m	g/m ² QW
N	:	37		7		8	1	12		20		5		5
	Total	Treatmt Rel	Total	Treatmt Rel	Total	Treatmt Rel	Total	Treatmt Rel	Total	Treatmt Rel	Total	Treatmt Rel	Total	Treatmt Rel
TEAE ≥15%	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Fatigue	15 (41)	12 (32)	4 (57)	4 (57)	1 (13)	0	7 (58)	5 (42)	8 (40)	5 (25)	2 (40)	2 (40)	1 (20)	1 (20)
Nausea	14 (38)	13 (35)	5 (71)	4 (57)	3 (38)	3 (38)	4 (33)	4 (33)	7 (35)	7 (35)	1 (20)	1 (20)	1 (20)	1 (20)
Diarrhea	12 (32)	9 (24)	4 (57)	3 (43)	3 (38)	2 (25)	2 (17)	1 (8)	5 (25)	3 (15)	0	0	3 (60)	3 (60)
Pyrexia	12 (32)	8 (22)	2 (29)	1 (14)	4 (50)	2 (25)	1 (8)	2 (25)	5 (25)	4 (20)	2 (40)	1 (20)	3 (60)	2 (40)
Anemia	12 (32)	6 (16)	2 (29)	1 (14)	2 (25)	0	6 (50)	4 (33)	8 (40)	4 (20)	0	0	2 (40)	1 (20)
Decreased appetite	12 (32)	8 (22)	3 (43)	3 (43)	1 (13)	1 (13)	8 (67)	4 (33)	9 (45)	5 (25)	0	0	0	0
Constipation	11 (30)	2 (5)	2 (29)	1 (14)	2 (25)	0	3 (25)	0	5 (25)	0	1 (20)	0	3 (60)	1 (20)
Urinary tract infection	10 (27)	0	2 (29)	0	5 (63)	0	1 (8)	0	6 (30)	0	1 (20)	0	1 (20)	0
Neutrophil count decrease	8 (22)	8 (22)	0	0	0	0	4 (33)	4 (33)	4 (20)	4 (20)	1 (20)	1 (20)	3 (60)	3 (60)
Asthenia	9 (24)	9 (24)	1 (14)	1 (14)	2 (25)	2 (25)	1 (8)	1 (8)	3 (15)	3 (15)	2 (40)	2 (40)	3 (60)	3 (60)
Peripheral neuropathy	9 (24)	7 (19)	2 (29)	2 (29)	4 (50)	4 (50)	1 (8)	1 (8)	5 (25)	5 (25)	1 (20)	0	1 (20)	0
Peripheral sensory neuropathy	4 (11)	3 (8)	0	0	2 (25)	2 (25)	1 (8)	1 (8)	3 (15)	3 (15)	0	0	1 (20)	0
Other peripheral neuropathy	5 (14)	4 (11)	2 (29)	2 (29)	2 (25)	2 (25)	0	0	2 (10)	2 (10)	1 (20)	0	0	0
Abdominal pain	8 (22)	1 (3)	2 (29)	1 (14)	1 (13)	0	3 (25)	0	4 (20)	0	0	0	2 (40)	0
Pruritus	7 (19)	5 (14)	3 (43)	3 (43)	0	0	1 (8)	0	1 (5)	0	2 (40)	1 (20)	1 (20)	1 (20)
Alopecia	7 (19)	7 (19)	0	0	3 (38)	3 (38)	1 (8)	1 (8)	4 (20)	4 (20)	1 (20)	1 (20)	2 (40)	2 (40)
Rash*	7 (19)	5 (14)	2 (29)	2 (29)	2 (25)	2 (25)	2 (17)	0	4 (20)	2 (10)	1 (20)	1 (20)	0	0
Back pain	6 (16)	0	1 (14)	0	2 (25)	0	2 (17)	0	4 (20)	0	0	0	1 (20)	0
Hypokalemia	6 (16)	2 (5)	1 (14)	0	0	0	4 (33)	1 (8)	4 (20)	1 (5)	0	0	1 (20)	1 (20)
Hypomagnesia	6 (16)	2 (5)	1 (14)	1 (14)	1 (13)	0	3 (25)	0	4 (20)	0	0	0	1 (20)	1 (20)


*Of the 7 rash TEAEs, 6 were Gr1 and 1 was Gr2. Of the 5 rash TRAEs, 4 were Gr1 and 1 was Gr2.

Rash patients in 5mg/m² QW UC cohort were rash chest (Gr1) and eczema (Gr2). Remaining rash cases in other cohorts were rash bilateral forearms, maculopapular, photosensitivity, urticaria, rash chest and rash not otherwise specified.



Enfortumab vedotin: Rash incidence in Phase 1 and label

Table S2. Treatment-Emergent Adverse Events of Special Interest¹



[†]Grade 4

1. Rosenberg, et al., "EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma" Journal of Clinical Oncology, 2020 Apr 1; 38(10): 1041–1049


2. Padcev FDA Label, July 2021

bicycle therapeutics

Enfortumab vedotin: Rash incidence, severity, warning label and recent articles

May 2022

- FDA Label revised July 2021 to include Black Box warning
- Event reports have since been published





PADCEV.

Initial U.S. Approval: 2019

Necrolysis (TEN).

(5.1) (6.1)

BT5528 Monotherapy EphA2



BT5528: EphA2 background - Target for BT5528 and MEDI-547 ADC

Erythropoietin-producing hepatocellular A2 receptor: member of Eph subfamily of receptor tyrosine kinases

Internal	Target	Modality	Pre- clinical	IND- enabling	Phase I	Phase II
bicycle therapeutics	EphA2	<i>Bicycle®</i> Toxin Conjugate				

- Regulates cell migration, adhesion, proliferation
 and differentiation
- Overexpressed in human cancers and correlates with tumor progression
- Development of MEDI-547 (MedImmune) in ovarian cancer was halted following serious bleeding events in phase I

"The bleeding and coagulation events observed in humans showed similarities to those evident in rats and monkeys. In all three species, increased activated partial thromboplastin time, increased fibrinogen/fibrin degradation product, and increased fibrin D-dimer were reported. Monkeys had red/ blood discharge from the nose, mouth, gums."¹

1. Annunziata, Christina M., et al. "Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors." *Investigational new drugs* 31.1 (2013): 77-84.



BT5528: Phase I dose escalation trial; overview of patient demographics and key adverse events

Demographics		Adverse events (AEs)	Related Gr \geq 3 AE N=13 patients ¹	
Total	24 (100%)		N=15 patients	
Age, years,		Neutropenia	N=8	
median (range)	65.5 (49-76)	Anemia	N=2	
Sex, n (%)		Pneumonitis	N=2	
Male	7 (29%)	Fatigue	N=1	
Female	17 (71%)	Ileus	N=1	
ECOG, n (%)		Tumor Lysis Syndrome	N=1	
0 (Good performance status)	11 (46%)	Bleeding disorders	N=0	
1	13 (54%)	Conjunctival disorders	N=0	
2+	0 (0%)		N-0	
Prior therapies,	7 (1 10)	Cutaneous events	N=0	
median (range)	7 (1-16)	Neuropathy	N=0	

• Total number of AEs: 235¹

• AEs related to BT5528: 101¹

 Transient Gr3/4 neutropenia at 8.5mg/m² dose¹

 DLTs at 10mg/m²: pneumonitis and fatigue¹

 Other toxicities (<Gr 3) predominantly hematological and GI¹

 Two Gr5 events observed, one following data cut-off



1. Data as of 14Jul21

30


BT5528: Preliminary responses observed during Phase I dose escalation trial

Responses observed:

Ovarian

- 1 PR¹ of 8 ovarian cancer patients, PR observed by month 4
- 4 of 5 with EphA2 staining showed some shrinkage

Change in target lesion size relative to baseline




1. Partial responses under response evaluation criteria in solid tumors (RECIST) version 1.1. Data as of 14Jul21

Urothelial


- 2 of 2 PRs¹, both at 2 months
- Both responses by first scan

Change in target lesion size relative to baseline






BT5528: Emerging observed relationship between EphA2 staining and responses



Data as of 14Jul21

BT5528 expansion: overall trial design



BT5528: Phase I dose escalation preliminary conclusions and next steps

BT5528 is a first-in-class *Bicycle®* toxin conjugate



Preliminary conclusions

- No evidence of BT5528 clotting abnormalities vs multiple disseminated intravascular coagulation events for MEDI-547 ADC
- Doses tolerated within expected therapeutic range; preliminary anti-tumor activity observed in two tumor types (ovarian and urothelial)
- Additional potential points of differentiation: no significant indications of neuropathy, eye and skin toxicities observed in BT5528 clinical trial as reported in interim Phase I dose escalation trial update on 70ct21.
- Preliminary findings indicate activity associated with tumor expression


Preparations underway for expansion cohorts in multiple tumor types Recommended Phase II dose of 6.5mg/m² Q2W



BT7480 Nectin-4/CD137



Bicycle TICA™ – Tumor-targeted Immune Cell Agonists join immune cell-engaging and tumor-targeting Bicycles






BT7480 entered clinic Q4 2021

Nectin-4 and CD137 co-expressed in a variety of human tumors

- BT7480 binds to Nectin-4 (across species) and CD137 (human, non-human primates) with high affinity. Exquisite selectivity observed in preclinical studies – no binding seen with >5,000 other membrane proteins.
- BT7480 well-tolerated in preclinical species, with no liver tox
- BT7480 is ca. 30x smaller than comparator biologics
- US IND cleared 17Sept21
 - 9 sites selected
 - QW dosing initially with dosing adjustment to $\ensuremath{\mathsf{Q2W}}$

Entered clinic Q4 2021




therapeutics


Upcoming Milestones





We believe we are well positioned to be the next generation of targeted oncology therapeutics

Tumor targeting Bicycles










Bicycle Toxin Conjugates®

Bicycle® TICAs



• BT7480 entered Phase I Q4 2021

Clinical signal observed

molecules

Generalizable to other payloads

 Intend to build on current clinical trial observations with "wave" of 3rd Gen

- BT7455 in IND enabling studies
- We believe our platform uniquely suited to tumor specific IO modulation
- Generalizable to multiple receptor classes

3rd Gen BTCs

 Broaden indications with additional targets and payloads

2nd Gen IO

- Tumor cell specific NK cell engagers in optimization
- Multi-targeted molecules in discovery

Internal & external pipeline combinations

- Short $t_{\mbox{\tiny 1/2}}$ critical for sequencing
- Current data provides compelling biological rationale for combination of cytotoxic BTC[™] with *Bicycle* TICAs and / or PD1



BREADTH

May 2022

Looking forward

BT5528 - plan to initiate expansion cohorts in 2022

BT8009 – further update later in 2022

BT7480 – dose escalation is ongoing (first patient dosed in Q4 2021)

Third generation *Bicycle* Toxin Conjugates[®] and NK cell engagers are in development



Appendix



BT8009: Low incidence of neutropenia¹ below 7.5mg/m² QW

Dose (mg/m ²)	Tumor	Highest Grade	Day of Onset	Resolved?	Dose Reduced?
5 QW	Pancreatic	4	20	Yes	Yes
5 QW	Breast	2	8	No	No
5 QW	Pancreatic	2	6	No	No
5 QW	NSCLC	1	21	No	No
5 QW	Ovarian ²	4	14	Yes	Yes
7.5 Q2W	Bladder	1	15	Yes	No
7.5 QW	Bladder ²	4	14	Yes	Yes
7.5 QW	Bladder	3	15	Yes	No
7.5 QW	NSCLC	1	64	No	No
7.5 QW	Bladder	4	15	Yes	No

1. Neutropenia includes 8 cases of neutrophil count decreases and 2 cases recorded as neutropenia

2. Recorded as neutropenia patients



BT8009: Neuropathy was limited to Grade 1-2 treatment-related events in patients with prior history of nerve damaging therapies

Dose (mg/m²)	Tumor	Highest Grade	Dose Reduced?	# Prior Lines of Therapies*
2.5 QW	Bladder (PD)	2	No	2
2.5 QW	Bladder (PR)	1	No	2
5 QW	Bladder (PR)	1	No	3
5 QW	Bladder (PR)	2	Yes	2
5 QW	Bladder (SD)	1	No	2
5 QW	Bladder (PR)	1	No	3
5 QW	Pancreatic (PD)	1	No	3

* All patients previously treated with platinum (60-90% neuropathy incidence: Kanat O, Ertas H, Caner B. World J Clin Oncol. 2017;8(4):329-335).



BT8009 parent and payload PK profile

- BT8009 demonstrates linear pharmacokinetics in humans. BT8009 has an elimination half-life of ${\sim}0.7~{\rm h}$
- The mean per dose exposure (AUC) of unconjugated MMAE from BT8009 dosed at 5mg/m² (equivalent to a dose 0.86 mg/m² of MMAE) was 829 ng.h/ml (CV 75%)
- Mean MMAE Cmax from BT8009 dosed at 5mg/m² was 18.4 ng/mL (CV 46%)
- The elimination half-life for MMAE was 2.3 days after BT8009 dosed at $5 mg/m^2$

Enfortumab vedotin parent and payload PK profile*

- Enfortumab vedotin has an elimination half-life of ~3.6 days
- The per dose exposure (AUC) of unconjugated MMAE from enfortumab vedotin dosed at 1.25mg/kg (equivalent to a dose 0.85 mg/m² MMAE) was estimated to be 680 ng.h/mL* (CV 59%)
- Mean MMAE Cmax from a 1.25mg/kg dose of enfortumab vedotin was 5.5 ng/mL (CV 55%)
- The elimination half-life for MMAE was 2.6 days after enfortumab vedotin dosed at 1.25mg/kg

*Enfortumab vedotin data are from Padcev USPI (Nov 2021). MMAE data estimated from MMAE AUC0-28d [mean(±SD): 85(50) ng·d/mL] after 1st treatment cycle of 1.25 mg/kg EV on days 1, 8 and 15 of a 28-day cycle.

Molecular weight is 149022 Da for enfortumab vedotin with a drug antibody ratio of 3.8

